STAA News and Press, STAAR Surgical Company From 04/19/23

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close. STAAR wi...

2023-03-29 07:26:07 ET STAAR Surgical ( NASDAQ: STAA ) has announced the appointment of Warren Foust as chief operating officer. Foust was serving as worldwide president for Johnson & Johnson Vision since December 2019. He managed the global surgical business at Johnso...

New Positions Demonstrate Increased Commitment and Focus on Continued Industry Leading Growth STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced Warren Foust has been named Chief Operating Officer and ...

2023-03-06 11:22:10 ET Summary STAA is a wonderful business selling at a fair price. STAA's business model is straightforward and the CEO does not have to be a genius to run it so long as he follows the playbook that Caren Mason laid out in my opinion. STAA has a dominant posi...

Summary Despite facing headwinds in China, STAAR Surgical Company was able to boast growing revenues in Q4 2022. It enjoyed growing revenues in all of its key geographic markets. It enjoyed growing revenues in all of its key geographic markets. This was largely due to the positive a...

STAAR Surgical Company (STAA) Q4 2022 Earnings Conference Call February 21, 2023 16:30 ET Company Participants Brian Moore - Vice President of Investor, Media Relations & Corporate Development Tom Frinzi - President, Chief Executive Officer & Chairman Patrick W...

STAAR Surgical Company ( NASDAQ: STAA ) dropped ~7% post-market Tuesday after the maker of implantable eye lenses indicated a lower-than-expected outlook for the full year with its Q4 2022 results. The company’s reaffirmed guidance for the full year, implying $340M in net s...

STAAR Surgical press release ( NASDAQ: STAA ): Q4 Non-GAAP EPS of $0.14 in-line. Revenue of $64.04M (+8.5% Y/Y) misses by $0.4M . ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21% from Prior Year Quarter ICL Units Up 20% fro...

ICL Unit Growth Up 33% Y/Y in Fiscal 2022 STAAR Reaffirms Outlook for Strong Trajectory of Growth in 2023 STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quar...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 30, 2022, on Tuesday, Fe...